ArticleFrontiers in immunology2022
The potential risk factors of early-onset post-stroke depression from immuno-inflammatory perspective.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Predictive roles of inflammatory indicators (NLR, PLR, LMR and SII) in poststroke depression rehabilitation: a systematic review.Frontiers in neurology · 2026Pooled it
- The Therapeutic Potential of Mesenchymal Stem Cells in Post-Stroke Depression.International journal of molecular sciences · 2026Review
- The Immunologic Underpinnings of Post-Stroke Depression.Biological psychiatry global open science · 2025Review
- Impact of insulin resistance on post-stroke depression and outcomes in diabetes.Journal of diabetes investigation · 2025Article
- The Impact of Post-stroke Depression and Physical Fatigue on Functional Status.Actas espanolas de psiquiatria · 2025Article
- Cilostazol-inhibited RhoA/NF-κB signaling mitigates hippocampal inflammation and post-stroke depression.Frontiers in pharmacology · 2025Article
- Post stroke depression: pathogenesis and molecular mechanisms of natural product-based interventions.Frontiers in pharmacology · 2025Review
- Is Serum VEGF-A Level an Indicator of Early-Onset Poststroke Depression?Medicina (Kaunas, Lithuania) · 2024Article
- Efficacy of acupuncture in the treatment of post-stroke depression: A study protocol of a randomized controlled trial.PloS one · 2024Article
- Efficacy and safety of acupuncture treatment for post-stroke depression: A protocol for systematic review and meta-analysis.PloS one · 2024Article
- Revealing genetic causality between blood-based biomarkers and major depression in east Asian ancestry.Frontiers in psychiatry · 2024Article
- Astrocytes in Post-Stroke Depression: Roles in Inflammation, Neurotransmission, and Neurotrophin Signaling.Cellular and molecular neurobiology · 2023Review
- Higher serum lipocalin 2 is associated with post-stroke depression at discharge.BMC neurology · 2023Article
- Luteolin and triptolide: Potential therapeutic compounds for post-stroke depression via protein STAT.Heliyon · 2023Article
- Serum alkaline phosphatase was independently associated with depression in patients with cerebrovascular disease.Frontiers in psychiatry · 2023Article
- The role of indoleamine 2,3-dioxygenase 1 in early-onset post-stroke depression.Frontiers in immunology · 2023Article
- Pathological stratification and therapeutic implications for post-stroke depression based on a multidimensional biomarker panel: a narrative review.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mounting evidence strongly uncovered that peripheral immuno-inflammatory response induced by acute stroke is associated with the appearance of post-stroke depression (PSD), but the mechanism remains unclear. Methods: 103 stroke patients were assessed at 2 weeks after onset using Diagnostic and Statistical Manual of Mental Disorders, 5th edition and then divided into PSD and non-PSD groups. Polymorphisms of inflammatory molecules (interleukin [IL]-1β, IL-6, IL-10, IL-18, tumor necrosis factor-α [TNF-α], interferon-γ [IFN-γ] and C-reactive protein [CRP]), complete blood count parameters, splenic attenuation (SA) and splenic volume (SV) on unenhanced chest computed tomography, demographic and other clinical characteristics were obtained. Binary logistic regression model was used to analyze the associations between inflammation-related factors and the occurrence of PSD at 2 weeks after stroke. Results: 49 patients were diagnosed with PSD at 2 weeks after onset (early-onset PSD). The C/T genotypes of CRP rs2794520 and rs1205 were less in PSD group than non-PSD group (both adjusted odds ratio = 3.364; 95%CI: 1.039-10.898; Conclusions: CRP polymorphisms, SA based on CRP genotype, and peripheral monocytes are associated with the risk of early-onset PSD, suggesting peripheral immuno-inflammatory activities elicited by stroke in its aetiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.